|
|
Article: AVANIR Pharmaceuticals Presents Data on Novel Allergy/Asthma Compound at AAAAI National Meeting.
- Article from:
- PR Newswire
- Article date:
- March 10, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
AVANIR Pharmaceuticals today announced that it presented data on AVP 13358, a novel compound for the treatment of asthma and allergy, at the 2003 national meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI). AVANIR's orally active compound is designed to act early in the body's response to allergens by pre-empting the production or release of mediators involved in the pathogenesis of asthma and allergic rhinitis. The approach is unique because it selectively targets both the production of the ultimate mediator (IgE antibodies) and a critical group of cytokines (Th2) thought to regulate IgE's production. Existing drugs such as antihistamines act to ...
Related newspaper, magazine, and journal articles:
|
|
Article: AVANIR Pharmaceuticals to Announce First Fiscal ...
PR Newswire;
February 7, 2003 ;
700+ words
...AVANIR Pharmaceuticals will announce financial results ... entering the passcode # 6412665. AVANIR Pharmaceuticals, based in San Diego, is engaged ... of FRB | Weber Shandwick, for AVANIR Pharmaceuticals; or Patrice Saxon, Investor ...
|
|